11 research outputs found
Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection
The antibody response to SARS-CoV-2 has not yet fully defined, but the availability of sensitive and specific serological assays is crucial to observe the presence of specific antibodies against the human receptor binding domain (S-RBD) and high specificity ACE-2-binding antibodies or neutralizing antibodies (NT) in response to vaccines. Indeed, these peculiar antibodies should prevent viral interaction between RBD and AngiotensinConverting Enzyme 2 (ACE2) receptor, located on surface of host cells. In this study, 72 samples from 37 hospitalized COVID-19 patients and 35 not-hospitalized patients were analyzed longitudinally. The detection of SRBD and NT antibodies was carried out using CLIA tests. Hospitalized patients showed elevated serum levels of S-RBD (97.22%) and NT (77.78%) antibodies, differently, not-hospitalized, who were paucisymptomatic or asymptomatic patients, showed lower serum levels of SRBD (65.71%) and NT (38.14%) antibodies. The results suggest that the NT serum level is strongly related to disease severity (p < 0.001) and to the serum level of S-RBD antibodies (p < 0.0001)
Entire Genome of a Strain of Human Immunodeficiency Virus Type 1 with a Deletion of nef That Was Recovered 20 Years after Primary Infection: Large Pool of Proviruses with Deletions of env
We report the complete sequence analysis of the provirus harbored in a long-term nonprogressor (patient SG1) 20 years after the first infection with a human immunodeficiency virus type 1 strain lacking nef. The sequencing showed large deletions in the nef-nef and nef-U3 regions. Except for vpu, all of the other accessory genes were intact. The gag and pol genes did not show significant alterations. We found large deletions in env, spanning the V1, V2, V3, V4, and V5 regions. We believe that, when down-regulation of the class 1 major histocompatibility complex molecules is inhibited by the lack of nef function, the cells containing Env-defective molecules evade cytotoxic T lymphocyte killing and accumulate progressively
Scala di Valutazione degli stati depressivi: Valutazione fattoriale su un campione di 2300 adolescenti
Evaluation of serological anti-SARS-CoV-2 chemiluminescent immunoassays correlated to live virus neutralization test, for the detection of anti-RBD antibodies as a relevant alternative in COVID-19 large-scale neutralizing activity monitoring
The Spike-Receptor Binding Domain (S-RBD) is considered the most
antigenic protein in SARS-CoV-2 and probably the key player in
SARS-CoV-2 immune response. Quantitative immunoassays may help establish
an anti-RBD Abs threshold as an indication of protective immunity. Since
different immunoassays are commercial, the standard reference method for
the neutralizing activity is the live Virus Neutralization Test (VNT).
In this study, anti-RBD IgG levels were detected with two
chemiluminescent immunoassays in paucisympto-matic, symptomatic and
vaccinated subjects, and their neutralizing activity was correlated to
VNT titer, using SARS-CoV-2 original and British variant strains. Both
immunoassays confirmed higher anti-RBD Abs levels in vaccinated
subjects. Furthermore, despite different anti-RBD Abs median
concentrations between the immunoassays, a strong positive correlation
with VNT was observed. In conclusion, although the SARS-CoV-2 immune
response heterogeneity, the use of immunoassays can help in large-scale
monitoring of COVID-19 samples, becoming a valid alternative to VNT test
for diagnostic routine laboratories
T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers
Background: SARS-CoV-2 T-cells are crucial for long-term protection against reinfection. The aim was to demonstrate the Interferon-gamma Release Assay (IGRA) test could be useful for vaccination monitoring. Methods: In a prospective cohort of 98 vaccinated healthcare workers for SARS-CoV-2, we selected 23 people in low-antibodies (Group 1, N = 8), high-antibodies (Group 2, N = 9), and negative control groups (Group 3, N = 6). SARS-CoV-2-specific humoral and cellular responses were analyzed at 8 months after two doses of Pfizer BioNTech, evaluating anti-RBD (Receptor Binding Domain) and RBD-ACE2 (Angiotensin Converting Enzyme-2) blocking antibodies in sera through a Chemiluminescence Immunoassay (CLIA) and T-cells through the IGRA test in heparinized plasma. Moreover, lymphocyte subtyping was executed by a flow cytometer. Statistical analysis was performed. Results: The data confirmed that RBD and RBD-ACE2 blocking ACE2 antibody levels of Group 1 were significantly lower than Group 2; p < 0.001. However, T-cells showed no significant difference between Group 1 and Group 2. Conclusions: This work suggests the need for new strategies for booster doses administration
A Retrospective Study One-Year Survey from COVID-19: Three Waves and Three Patterns in Italy
Background: Since December 2019 an unprecedented coronavirus pandemic (COVID-19) in Italy and in all the world, has been spreading. This study is a retrospective overview of Italian popul
Characterization of Gut Microbiota Composition in Type 2 Diabetes Patients: A Population-Based Study
(1) Background: A clinical laboratory index to assess gut dysbiosis is the F/B ratio < 0.8. In fact, an elevated proportion of Firmicutes and a reduced population of Bacteroides in diabetes type 2 (T2D) subjects has been observed. This study aimed to detail the dysbiosis status in the Italian population, focusing on some pathogenic spectra (T2D) or metabolic disorders. (2) Material and methods: A quantity of 334 fecal samples was analyzed in order to perform genetic testing and sequencing. (3) Results: A trend in over imbalance was observed in the percentage of Proteobacteria (median value: 6.75%; interquartile range (IQR): 3.57–17.29%). A statistically significant association (χ2p = 0.033) was observed between type of dysbiosis and T2D, corresponding to an Odds Ratio (OR) of 1.86. It was noted that females with cystitis/candidiasis are significantly prevalent in T2D patients (p < 0.01; OR: 3.59; 95% CI: 1.43–8.99). Although, in non-diabetic males, a sugar craving is significantly associated with the rate of dysbiosis in non-diabetic males (p < 0.05; OR 1.07; 95% CI 1.00–1.16). (4) Conclusion: In T2D patients, the Bacteroidetes/Firmicutes ratio was biased in favor of Proteobacteria, to be expected due to the nutritional habits of the patients. Thus, T2D females had altered gut permeability favoring the development of infections in the vaginal tract
Characterization of Gut Microbiota Composition in Type 2 Diabetes Patients: A Population-Based Study
(1) Background: A clinical laboratory index to assess gut dysbiosis is the F/B ratio < 0.8. In fact, an elevated proportion of Firmicutes and a reduced population of Bacteroides in diabetes type 2 (T2D) subjects has been observed. This study aimed to detail the dysbiosis status in the Italian population, focusing on some pathogenic spectra (T2D) or metabolic disorders. (2) Material and methods: A quantity of 334 fecal samples was analyzed in order to perform genetic testing and sequencing. (3) Results: A trend in over imbalance was observed in the percentage of Proteobacteria (median value: 6.75%; interquartile range (IQR): 3.57-17.29%). A statistically significant association (chi(2) p = 0.033) was observed between type of dysbiosis and T2D, corresponding to an Odds Ratio (OR) of 1.86. It was noted that females with cystitis/candidiasis are significantly prevalent in T2D patients (p < 0.01; OR: 3.59; 95% CI: 1.43-8.99). Although, in non-diabetic males, a sugar craving is significantly associated with the rate of dysbiosis in non-diabetic males (p < 0.05; OR 1.07; 95% CI 1.00-1.16). (4) Conclusion: In T2D patients, the Bacteroidetes/Firmicutes ratio was biased in favor of Proteobacteria, to be expected due to the nutritional habits of the patients. Thus, T2D females had altered gut permeability favoring the development of infections in the vaginal tract
Evaluation of Natural and Vaccine-Induced Anti-SARS-CoV-2 Immunity: A Comparative Study between Different Groups of Volunteers
(1) Background: The production of anti-SARS-CoV-2 antibodies should help
minimize the severity of COVID-19 disease. Our focus was to investigate
and compare different vaccination schedules, monitoring circulating
S-RBD Ab (antibodies anti-Spike protein-Receptor Binding Domain) levels
after administering two doses in naive patients. Likewise,
vaccine-stimulated immunity in naive and previously infected patients
was compared. (2) Methods: We included 392 patients. Sera were evaluated
by Elecsys anti-SARS-CoV-2 S. Statistical analyses were conducted by
MedCalc and JASP. (3) Results: In COVID-19 patients, the median value of
Ab levels was 154 BAU/mL, stable up to 9 months after the infection.
From the data observed in vaccinated patients, higher median values were
recorded in COVID-19/Pfizer BioNTech (18913 BAU/mL) than in other groups
(Pfizer BioNTech: 1841; ChadOx1 961; heterologous vaccination: 2687)
BAU/mL. (4) Conclusions: In conclusion, a single booster dose given to
previously infected patients raised an antibody response much higher
than two doses given to naive individuals and heterologous vaccination
generated a robust persistent antibody response at high levels, steady
up to three months after administration